

Hyeon Jeong Suh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1095955/hyeon-jeong-suh-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

239
citations

7
h-index

12
g-index

12
ext. papers

320
ext. citations

5.6
avg, IF

3.84
L-index

#	Paper	IF	Citations
11	Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021 , 27, 928-931	10.2	66
10	Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021 , 27,	10.2	67
9	Clinical Characteristics of COVID-19: Risk Factors for Early Oxygen Requirement after Hospitalization. <i>Journal of Korean Medical Science</i> , 2021 , 36, e139	4.7	4
8	Antibody Responses One Year after Mild SARS-CoV-2 Infection. <i>Journal of Korean Medical Science</i> , 2021 , 36, e157	4.7	9
7	Prevalence of cryptococcal antigenemia in hospitalized patients with liver cirrhosis. <i>Medical Mycology</i> , 2020 , 58, 207-210	3.9	3
6	Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance. <i>Journal of Korean Medical Science</i> , 2020 , 35, e297	4.7	13
5	Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. <i>Emerging Infectious Diseases</i> , 2020 , 26, 2484-2487	10.2	50
4	The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	15
3	A Risk-Scoring System for Predicting Methicillin Resistance in Community-Onset Staphylococcus aureus Bacteremia in Korea. <i>Microbial Drug Resistance</i> , 2018 , 24, 556-562	2.9	1
2	Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 115-119	3.2	3
1	Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. <i>Infection and Chemotherapy</i> , 2017 , 49, 135-139	3.9	7